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Editorial on the Research Topic
Shankopathies: Shank Protein Deficiency-Induced Synaptic Diseases
SHANK (also known as ProSAP) proteins are postsynaptic core scaffolds involved in excitatory
synapse development, function, and plasticity. The three members of the SHANK family
(SHANK1, SHANK2, and SHANK3) differ in their temporal and regional expression patterns
in the central nervous system and non-neuronal tissue during development. Mutations in the
cognate genes are associated with various neuropsychiatric conditions, such as autism spectrum
disorders, Phelan-McDermid syndrome, intellectual disability, schizophrenia, and bipolar disorder.
Exactly how defects in SHANK proteins contribute to these conditions is currently under
active investigation.
The present Research Topic provides an overview of current knowledge on the involvement of
SHANK genes in neuropsychiatric disorders. Shankopathies are explored at different scales: genes,
proteins, cells, synapses, neural circuits, behaviors, and environment. For example, Eltokhi et al.
observed that the large phenotypic diversity of patients carrying SHANK2 mutations is reflected
in the phenotypic diversity displayed by the various Shank2 mouse models. Hassani Nia and
Kreienkamp reviewed the effects of Shank3mutations on the gene, protein, and synaptic signaling.
Both reviews provide a comprehensive state-of-the-art overview on SHANK2 and SHANK3
different scales. An example of how mouse models can closely mimic human Shankopathies was
provided by the comprehensive characterization of the Shank3Q321R knock-in model conducted
by Yoo et al..
The other contributions address two major questions for Shankopathies: (i) Are there specific
modulating factors for Shankopathies and (ii) Which brain regions are specifically affected
by Shankopathies?
Concerning the first question, three putative modulating factors were examined; namely,
pharmacological intervention (pharmacological modulation of phenotypes), sexual hormones,
and zinc. Sungur et al. explored whether Shank1 mutant mice and control mice were equally
sensitive to amphetamine and methylenedioxymethamphetamine. In Shank2 mutant mice, Ey
et al. demonstrated that the abnormal social behavior of Shank2 knockout mice was associated
with a deficit in social motivation, but with an intact social recognition phenotype. They also
highlighted that methylphenidate is ineffective in restoring typical activity levels in hyperactive
Shank2 knockout mice. By contrast, Berkel et al. examined the role of an inherent modulating
factor; namely, sexual hormones, on Shank1, Shank2, and Shank3 gene transcription and protein
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levels. The role of sexual hormones as transcriptional fine-
tuners, especially shortly before or after birth, might explain
sex-related differences in patients and animal models. Finally,
zinc was identified as a potentially major modulating factor in
Shankopathies, given its role in recruiting Shank2 and Shank3
at synapses, as well as having a key role in the gastro-intestinal
tract, as reviewed by Hagmeyer et al.. At the molecular level,
the mode of regulation of AMPA receptor (AMPAR) subunit
composition by Shank2, Shank3 and zinc was explored by Ha
et al.. Zinc regulated the switch during development of AMPARs
lacking GluA2 to AMPARs containing GluA2, while Shank2 and
Shank3 also regulated this process. At the scale of the organism,
Fourie et al. tested the effect of long-term zinc supplementation in
alimentation of the Shank31ex13−16 mouse model. Importantly,
some aspects of synaptic transmission and some behavioral
traits, such as self-grooming, were rescued. Taken together,
the studies on zinc presented in this Research Topic present
evidence that zinc is a promising potential new therapeutic agent
for Shankopathies.
Regarding the second question on brain regions specifically
affected by Shankopathies, different approaches were used to
investigate the effect of Shank mutations at the different scales
of observation. Yoo et al. highlighted that a conditional Shank3
knockout (targeting exons 14–16, encoding the PDZ domain)
in GABAergic neurons (enriched in the striatum) induces
a strong reduction of excitatory synaptic inputs onto dorsal
striatal neurons as observed in global Shank31ex14−16 mutant
mice. However, the conditional knockout leads to milder social
deficits and stereotyped behaviors than global Shank31ex14−16
mutant mice. Using magnetic resonance imaging (MRI), Schoen
et al. examined mouse brain anatomy during development
showing that total brain volume, cerebellar volume, and cortical
thickness were unaffected in homozygous and heterozygous
Shank3 mutant mice and the prenatal zinc deficiency model
compared to wild-type controls. By contrast, the striatal volume
and the globus pallidus volume were increased in both models,
while the changes in the thalamus were reduced in the Shank3
mousemodel and increased in the prenatal zinc deficiencymouse
model. Transcriptomic analyses allowed (Jin et al.) to identify
brain region-specific modulation of gene expression in different
Shank3 models, across age classes and between brain regions
(prefrontal cortex, striatum, and hippocampus). This analysis
highlighted an important modulation of the expression of
myelin-related and ribosome-related genes. At the protein level,
Heise et al. found that Shank2 and Shank3mutant mice displayed
a reduced expression of receptors specific to excitatory synaptic
transmission in the striatum and in the thalamus (for Shank2
also in the cortex and cerebellum). These models were compared
to another mouse model of neurodevelopmental disorders, the
Cntn4 mutant that displays increased surface expression of
glutamatergic receptors (GluA1 and GluA2) in the striatum or
downregulation of GABAergic receptors (GABAA) in several
brain regions. Finally, the involvement of the reward system was
examined directly and indirectly. In the direct approach, Bariselli
et al. knocked down Shank3 in the ventral tegmental area in
mice and observed a dysfunction in social-seeking behavior. The
indirect approach concerned the characterization of a Shank2
model in another species, namely the Shank21ex31 mutant rat,
characterized by Modi et al.. Shank21ex31 mutant rats displayed
an atypically high motivation to collect food reward, in parallel
with social deficits, impaired learning, increased activity, and
repetitive circling, combined with increased striatal activity and
decreased hippocampal function.
In summary, this Research Topic provided a multi-scale
overview of the current state of knowledge on Shankopathies.
The research studies contribute to the understanding of the
spectrum of disorders related to SHANK mutations, as well
as providing prospects for new potential therapeutic strategies,
targeting specific brain regions or modulating factors.
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